Article
Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
Hematology (Amsterdam, Netherlands) - 1 Apr 2015
de Lima Luciene Terezina, Bueno Carolina Tosin, Vivona Douglas, Hirata Rosario Domiguez Crespo, Hirata Mario Hiroyuki, Hungria Vania Tiestsche de Moraes, Chiattone Carlos Sérgio, Zanichelli Maria Aparecida, Chauffaille Maria de Lourdes Lopes Ferrari, Guerra-Shinohara Elvira Maria
Abstract excerpt
BACKGROUND: Genetic variations in membrane transporters may contribute to imatinib mesylate (IM) resistance in chronic myeloid leukemia (CML). Objective To investigate the relationship between SLCO1B3, SLCO1A2, and ABCA3 polymorphisms and IM response in CML patients. METHODS: Patients in chronic phase CML (N = 118) were studied. All patients were treated with a standard dose of IM (400 mg/day) and classified into...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
